EKF Diagnostics, the in vitro diagnostics company, has appointed Luke Daum PhD as Scientific Director (CSO), bringing a wealth of expertise in molecular diagnostics to EKF’s management team. Inventor of PrimeStore® MTM (Molecular Transport Medium), the FDA approved, CE IVD marked specimen collection device that deactivates viruses, Dr. Daum has significant industry experience leading teams from concept to products to success. In the fight against COVID-19, more than 50 million PrimeStore MTM vials have now been distributed worldwide, enabling safe and reliable molecular testing.
Luke Daum Ph.D. joins EKF Diagnostics as Scientific Director. Image Credit: EKF Diagnostics
Dr Daum joins EKF after working for Longhorn Vaccines and Diagnostics, a molecular diagnostics company focused on the rapid detection and characterization of infectious diseases, where he was Scientific Co-Founder, CSO and Executive Vice President. Previously, he was a civilian scientist in the United States Department of Defense, originally and director of the United States Air Force’s Molecular Influenza Strain Surveillance Laboratory. He is also a co-author of publications with the US CDC and has presented his research on influenza and tuberculosis at scientific conferences around the world.
Holder of a doctorate from the Cellular and molecular biology program at the University of Texas and a second doctorate (Honoris causa) of Central Michigan University for his contributions to the field of infectious disease detection, Dr. Daum has published over 30 peer-reviewed articles and holds 12 U.S. and international scientific product patents.
In his role as Scientific Director of EKF Diagnostics, Dr Daum will provide valuable scientific leadership for the research and development of EKF’s broad portfolio of clinical diagnostics products and support the company’s growth of its molecular diagnostics offering and of life sciences.
The future of EKF’s expansion into products and services that improve the detection of diagnostic diseases is very exciting, and I look forward to using my experience to help advance the growth of EKF in clinical centers. high-throughput diagnostic tests, clinics and point-of-care.“
Luke Daum PhD, CSO, EKF Diagnostics
EKF’s new CEO, Mike Salter, said: “We are delighted to welcome Dr Luke Daum to the EKF leadership team as a highly respected and valued member of the life science and diagnostic community. His vast knowledge and experience in developing successful products and knowledge in molecular diagnostics will be instrumental as we continue to build the significant momentum we have made to support the response to the COVID-19 pandemic.“
Mike Salter’s appointment as CEO will be effective October 1, 2021. As current President of the US business of EKF Diagnostics, he has been responsible for all US facilities including sales, operations and regulatory affairs, and also focuses on EKF’s life sciences. in Elkhart, Indiana. Previously, Mike worked at GE Healthcare where he was General Manager of the Custom Molecular Reagent business within GE Life Sciences.
Mike has over 35 years of experience in the life sciences and diagnostics industry, including 33 years with GE and Amersham in various roles in the UK, Canada and the US. Since joining EKF in October 2017, he has been responsible for overseeing the growth of EKF’s Diabetes and Hematology business in the United States and, leveraging his sales network, has secured license, increased production capacity and secured orders for EKF’s COVID-19 sample collection. kits business.